Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

CNW/ -- (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 billion in annual sales or be clinical "game changers" in the next five ...

Two anti-transferrin receptor (TfR) nanobodies, V H H123 specific for mouse TfR and V H H188 specific for human TfR (huTfR) were used to track transplants non-invasively by PET/CT in mouse models, ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

PSP-001 is under clinical development by Prosit Sole Biotechnology (Beijing) and currently in Phase I for Norovirus Infections.

and is also exploring use of the drug in combination with current therapies including pegylated interferon (PegIFN) and its experimental immunotherapies. GSK licensed the drug from longstanding ...

Nanoparticles (NPs) are versatile tools in various applications, particularly in the biomedical fields. To understand their behavior within biological systems, it is crucial to measure their ...

After hours: January 3 at 7:46:57 PM EST Loading Chart for RLYB ...

Nanomedicine. 2012;7(8):1253-1271. Liposomes Liposomes are self-assembled artificial vesicles developed from amphiphilic phospholipids. These vesicles consist of a spherical bilayer structure ...